SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for VerifyMe, Inc. (VRME, VRMEW) (CIK 0001104038) (OPNW) — May 8, 2020

VerifyMe, Inc. (VRME, VRMEW) (CIK 0001104038)
Date: May 8, 2020 · CIK: 0001104038 · Accession: 0000000000-20-004063

AI Filing Summary & Sentiment

File numbers found in text: 333-237950

Date
May 8, 2020
Author
Not clearly detected
Form
UPLOAD
Company
VerifyMe, Inc. (VRME, VRMEW) (CIK 0001104038)

Letter

United States securities and exchange commission logo May 8, 2020 Patrick White Chief Executive Officer VerifyMe, Inc. 75 S. Clinton Ave, Suite 510 Rochester, NY 14604 Re:VerifyMe, Inc. Registration Statement on Form S-1 Filed May 1, 2020 File No. 333-237950 Dear Mr. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
United States securities and exchange commission logo
May 8, 2020
Patrick White
Chief Executive Officer
VerifyMe, Inc.
75 S. Clinton Ave, Suite 510
Rochester, NY 14604
Re:VerifyMe, Inc.
Registration Statement on Form S-1
Filed May 1, 2020
File No. 333-237950
Dear Mr. White:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences